4th PROGRAM

Day’s Theme: The Creative Process and building value


 

  • 8:30 AM | Registration/Administrative Continental Breakfast

 


 

  • 9:00 AM | Session 1:  Welcome and Opening Remarks:

 

Prof’ Asher Tishler, Dean Faculty of Management, Tel Aviv University

Course Directors

 

Acknowledgement of Sponsors

 

Course Infrastructure:

 

Introduction to Program Structure

Review of required assignments

Formation of study teams

 


 

  • 9:30 AM | Session 2:  Opening Keynote Address

Introduction: Robert Goldberg, PhD, Vice President, Center for Medicine in the Public Interest

 

Frank L. Douglas, Ph.D., M.D. President & CEO, Austen BioInnovation Institute in Akron

 

“How To Move From Discovery To Commercialization”

 


 

  • 10.30 AM | Session 3: The Persuasive Pitch, Part  1: Introduction of course participants

 

Moderators: Kim Cooper , CEO, Kim Cooper Associates, Leadership & Communications

 

Benny Zeevi, M.D. Managing General Partner, DFJ Tamir Fishman Ventures, Board Member ILSI & IVA

David Frank, Managing Director MEDX Associates LLC – Presentation Style from the Executive Technique

 

In order to give participants a chance to learn more about their colleagues in the course, and as the first part of our special focus on presentations, we are asking each participant to prepare to deliver a 3-5 minute presentation, using 2-4 power point slides, to introduce yourself and your company to the group

 


 

  • 12:30 AM | Networking Luncheon

 


 

  • 13.30 AM | Session 4:   Lessons learned from our experience: A panel of life science serial entrepreneurs

In this session we will have several leading entrepreneurs in life science telling their experience

 

Moderators:  David Cassack, Managing Partners and co-founders of Windhover.

 

Shimon Eckhouse, Co-founder and Chairman of Syneron Ltd. “Key success factors in new life science business ventures – a personal perspective”

 

Frank L. Douglas, Ph.D., M.D. President & CEO, Austen BioInnovation Institute in Akron

 

Ascher Shmulewitz, M.D., President Medegenesis

 


 

  • 3:00 PM | Session 5: Value Inflection Points in a Life Science Venture

 

When meeting with investors and prospective strategic partners, entrepreneurs will often hear questions that ask: Where are you in the value chain?” How does your business model reflect this?” “How do you describe your milestones and how are you managing towards them?” How do your milestones tie-in with your value inflection points?”  This session will consist of a brief overview of typical value inflection points for each type of product. The participants will be divided into small work groups, based on the nature of their companies, to discuss the value inflection points for their development scheme and offer one another critique. The groups will then reconvene and one example from each of devices, drugs and diagnostics will be reviewed by the faculty

 

Moderator: Stephen M. Sammut, Senior Fellow, Health Care Systems and Entrepreneurial  Programs, Wharton School, University of Pennsylvania. Venture Partner, Burrill & Company

 

Brent Ahrens, General Partner, Canaan Partners

 


 

  • 4.00 PM | Session 6 :Case Study

 

Faculty led discussion of a case prepared by the INSEAD Israel Research Centre:

 

“Deep Breeze Brings an Innovative Case to Market”

 

With participation of: Doron Nahmias, managing Director INSEAD Israel , Dr. Paivi Jokola Researcher INSEAD Israel, Yoav Cheluoche, Managing Partner, Aviv ventures

 


 

  • 5.00 PM | Bio – Break

 


 

  • 5:30 PM | Session 7: Keynote lecture:

 

Introduction: Brent Ahrens, General Partner, Canaan Partners

 

David Cassack, Managing Partners and co-founders of Windhover.

 

An overview of the medical device market

 


 

  • 6:30 PM | Session 8: Incorporating Reimbursement in the Company Development Strategy

 

Moderator: Robert Goldberg, PhD, Vice President, Center for Medicine in the Public Interest

 

Lambert Van Der Walde, Former CMS liaison to VCs, start ups and Wall Street

 

 

Steve Peskin, MD, MBA, Executive VP and Chief Medical Officer, MediMedia, USA

 


 

  • 8:00 PM | Adjourn for day

 


Day’s Theme: Strategy and Execution


 

  • 8:30 AM | Continental Breakfast

 


 

  • 9:00 AM | Session 9: Lecture

 

Developing consumer healthcare products: Proctor & Gamble, Develop and Connect Program

 

Lital Asher, Israel Innovation Leader & External Relations Manager

 


 

  • 09:30 AM | Session 10: Designing and Conducting Clinical Trials: From Proof of Concept to Marketing Success

 

This session provides an abbreviated view of the overall process and specific insight into planning for FDA regulations in light of strategy, financial needs, and the concerns of prospective partners and investors. Entrepreneurs need to understand that there is an increasing need to perform clinical studies to support medical device safety and performance claims. They also need to have a basic understanding of the activities, resources and costs associated with the design and conduct of clinical studies. The failure to incorporate an effective clinical strategy into new project planning can lead to significant project and funding delays or, worse, the failure of the project. This session will provide an overview of the increasing need for device clinical study data; key activities, resource needs and costs; and planning for the successful design and conduct of medical device clinical studies for acceptance in the United States and Europe, even when these studies are conducted outside of these regulatory jurisdictions.

 

Moderator: Benny Zeevi, M.D., Managing General Partner, DFJ Tamir Fishman Ventures

 

 

Dr. Dan Schultz ,M.D. Sr. Vice President, Medical Devices & Combination Products, Greenleaf Health, Former Director of FDA’s Center for Devices and Radiological Health (CDRH)

 


 

  • 11.30 AM | Bio Break

 


 

 

  • 12.00 PM | Session 11: Emerging Markets – Opportunities for Life Science companies?

 

 

Moderator: Stephen M. Sammut,Senior Fellow, Health Care Systems and Entrepreneurial  Programs, Wharton School, University of Pennsylvania, Venture Partner, Burrill & Company

 

Dr. Peter Lu, Partner, Infinity Private Equity Fund, China

 

David Frank, Managing Director MEDX Associates LLC

 

 

Gad Berdugo, Founder,  Explorium Capital Former Director and Sector Leader for global healthcare equity investment research at Lazard in New York

 


 

  • 1:30 PM | Networking Luncheon

 


 

  • 2:30 PM | Session 12: Keynote lecture

 

Steve Peskin, MD, MBA, Executive VP and Chief Medical Officer, MediMedia, USA

 

Digital and Social media (R)evolution: How Digital Communication Platforms and Tools are Transforming Life Sciences

 


 

  • 3:15 PM | Session 13: Capitalization of a life science Venture –Terms, Rounds etc…

 

Andrew Farquharson, Managing Director, DFJ InCube Ventures

 

Gad Berdugo, Founder,  Explorium Capital Former Director and Sector Leader for global healthcare equity investment research at Lazard in New York

 

Alon Sahar,Adv., Partner,  Herzog, Fox & Neeman- Terms and agreements

 

Naomi Herman, General Manager, SVB Israel Advisors Ltd

 


 

  • 4:15 PM | Case Study:

 

NanoPass

 

Moderators: Steve Sammut, Benny Zeevi

 

Presenter: Dr. Yotam Levin, CEO Nanopass

 


 

  • 5:00 PM | Bio – Break

 


 

  • 5:30 PM | Session 14:  The Persuasive Pitch, Part 2: Presenting Your Idea—and Yourself—With Purpose, Clarity, and Power

 

Kim Cooper , CEO, Kim Cooper Associates, Leadership & Communications

 


 

  • 6.30 PM | Session 15: Venture Capitalists and Entrepreneurs – A complex Relationship

 

Benny Zeevi, M.D. Managing General Partner, DFJ Tamir Fishman Ventures

 

Brent Ahrens, General Partner, Canaan Partners

 

David Cassack, Managing Partners and co-founders of Windhover

 

Andrew Farquharson, Managing Director, DFJ InCube Ventures

 


 

  • 8:00 PM | Dinner for Faculty and Participants

At the Green Vila, Tel Aviv University

 

Courtesy of Mintz Levin

Short lecture

 


Day’s Theme: Bringing the product to the market


 

  • 8:15 AM | Continental Breakfast

 


 

  • 8.45 AM | Keynote lecture:

 

Introduction: Benny Zeevi, M.D. Managing General Partner, DFJ Tamir Fishman Ventures, Board IVA

 

Keynote Theme: “Innovation in Interventional Cardiovascular Medicine: A Rapidly Moving Target!”

 

Martin Leon, M.D., Professor of Medicine, Associate Director, Center for Interventional Vascular Therapy, Columbia University Medical Center.

 


 

  • 9:45 AM | Session 14: Designing and Conducting Clinical Trials: From Proof of Concept to Marketing Success

 

This session provides an abbreviated view of the overall process and specific insight into planning for FDA regulations in light of strategy, financial needs, and the concerns of prospective partners and investors. Entrepreneurs need to understand that there is an increasing need to perform clinical studies to support medical device safety and performance claims. They also need to have a basic understanding of the activities, resources and costs associated with the design and conduct of clinical studies. The failure to incorporate an effective clinical strategy into new project planning can lead to significant project and funding delays or, worse, the failure of the project. This session will provide an overview of the increasing need for device clinical study data; key activities, resource needs and costs; and planning for the successful design and conduct of medical device clinical studies for acceptance in the United States and Europe, even when these studies are conducted outside of these regulatory jurisdictions.

 

Moderator: Robert Goldberg, PhD, Vice President, Center for Medicine in the Public Interest

 

 

Dr. Leonard Sacks, Deputy Director of the Office of Critical Path Programs from the FDA

 

Maria E. Donawa, M.D., President, Donawa Consulting, Medical Device Clinical Studies: Strategies for Success

 

Bruce Mackler, Senior advisor in FDA matters and FDA due diligence issues to financial/investment groups and companies.

 

 

Andy Weiss, President & CEO, CoAxia, former Vice President & General Manager of Medtronic Neurological.

 


 

  • 11:15 AM | Bio – Break

 


 

  • 11:45 AM | Session 15: Essentials of Pricing and Reimbursement

 

Moderator: Robert Goldberg, PhD, Vice President, Center for Medicine in the Public Interest

 

Lambert Van Der Walde, CMS, CMS liaison to VCs, start ups and Wall Street

Amir Inbar, CEO Mediclever, Reimbursement strategists in major European countries.

 

Susan Berson, Managing Member of Mintz levin Washington, D.C. office

 

Andy Weiss, President & CEO, CoAxia, former Vice President & General Manager of Medtronic Neurological.

 


 

 

  • 1:15 PM | Session 16: Case study on Pricing and Reimbursement or other case study

 

Moderator: Amir Inbar, CEO Mediclever,

 

Presenter: Adi Dagan, CEO of MCS

 


 

  • 1:45 PM | Luncheon

 


 

  • 2:15 PM | Session 17: Capitalization of a life science Venture –Terms, Rounds etc…

 

Andrew Farquharson, Managing Director, DFJ InCube Ventures

 

Andy Weiss, President & CEO, CoAxia, former Vice President & General Manager of Medtronic Neurological.

 

Alon Sahar,Adv., Partner,  Herzog, Fox & Neeman- Terms and agreements

 


 

  • 3:15 PM | Session 18: Post-luncheon Keynote :

Stan Rose, Ph.D former CEO of Nimblegen (acquired by Roche for $275M in August 2007), Genetic Microsystems (Affymetrix acquired for $175M in the early 2000’s)

 

“Successful Exit Strategies”

 


 

  • 3:45 PM | Session 19: Practical tips for CEOs, for survival and growth in tough financial environment- What not to do..and What to do

 

Moderator: Benny Zeevi, Managing Partner, DFJ Tamir Fishman Ventures

 

Israeli CEO’s- Prof’ Moshe Flugelman, President & CSO, MGVS

 

Andy Weiss, President & CEO, CoAxia, former Vice President & General Manager of Medtronic Neurological.

 

Brent Ahrens, General Partner, Canaan Partners

 


 

  • 4:30 PM | Bio – Break

 


 

  • 5:00 PM | Session 20: The Persuasive Pitch, Part 3: Presentations Workshop

 

Moderator: Kim Cooper – C.E.O, Kim Cooper Associates,    a communications consulting company

 

Three participants will present revised versions of their introductions from Sunday, and will receive feedback on both the written and spoken aspects of their presentations.

 


 

  • 6:00 PM | Program Adjournment

Session 21: Teams gather for “Take-aways Exercise”

 

Each participant will receive at registration a work-sheet to record for each session one major lesson or “take-away.” Teams will gather to discuss, compare notes, and develop one major take away for three sessions that will be assigned. Participants will have reviewed take-aways from Days 1 and 2 at the end of each day.

 


 

  • 6:45 PM | Program Adjournment